Jakarta, 8 July 2026 - Indonesia has once again taken an important step toward strengthening its self-reliance in health, with the launch of a Tetravalent mRNA-Based Dengue Vaccine Prototype developed using the preM-E gene from an Indonesian strain of the dengue virus. The prototype is the result of a research collaboration between Universitas Indonesia, Tsinghua University, and PT Etana Biotechnologies Indonesia (Etana),
Read MoreJakarta, June 2, 2026 - PT Etana Biotechnologies Indonesia (Etana) reaffirms its commitment to improving public health through vaccine innovation and development, with a particular focus on the Human Papillomavirus (HPV) vaccine. As a biopharmaceutical company focused on high-quality health products, Etana continues to deliver strategic solutions for cervical cancer prevention, which remains one of the leading causes of female mortality in Indonesia.
Read MoreJakarta, March 11, 2026 – In commemoration of World Kidney Day, PT Etana Biotechnologies Indonesia (Etana) is encouraging greater access to anemia therapy for patients with chronic kidney disease (CKD) in Indonesia. This initiative reflects Etana’s commitment to supporting comprehensive kidney disease management while helping improve patients’ quality of life in a sustainable manner.
Read MoreJakarta, February 1, 2026 - PT Etana Biotechnologies Indonesia (Etana), in commemoration of World Cancer Day (WCD) 2026 under the theme “United By Unique,” reaffirmed its commitment to building a comprehensive and sustainable cancer care ecosystem. Etana believes that overcoming cancer requires concrete action and strong cross-sector collaboration.
Read MoreJakarta, November 13, 2025 – PT Etana Biotechnologies Indonesia (Etana), together with CanSino Biologics Inc., has officially initiated the Phase I Clinical Trial of an inhaled Tuberculosis (TB) vaccine in Indonesia. This inhaled TB booster vaccine is a recombinant human adenovirus type 5–based vaccine and represents an innovative global TB booster designed for individuals who have previously received the Bacillus Calmette-Guérin (BCG) vaccine.
Read MoreYogyakarta, October 6, 2025 — PT Etana Biotechnologies Indonesia together with the Faculty of Pharmacy, Universitas Gadjah Mada (UGM) held the Indonesia Biopharmaceutical Summit (IBS) 2025, a strategic forum bringing together stakeholders from academia, industry, and government sectors. Carrying the theme “Shaping the Future of Biopharma in Indonesia”, this event serves as an important momentum to drive innovation and strengthen the biotechnology ecosystem toward national health sovereignty in Indonesia.
Read More
